目的 觀察阿托伐他汀聯(lián)合單硝酸異山梨酯治療冠心病心絞痛的臨床療效。方法 選取2015年7月-2016年6月平煤神馬醫(yī)療集團(tuán)總醫(yī)院收治的106例冠心病心絞痛患者，隨機(jī)分為對(duì)照組和治療組，每組各53例。對(duì)照組口服單硝酸異山梨酯片，20 mg/次，2次/d；治療組在對(duì)照組的基礎(chǔ)上睡前口服阿托伐他汀鈣片，20 mg/次，1次/d。兩組患者均連續(xù)治療4周。比較兩組患者治療前后臨床療效、臨床癥狀和心電圖改善情況，同時(shí)評(píng)價(jià)三酰甘油（TG）、膽固醇（CHO）、低密度脂蛋白（LDL-C）水平、高敏C反應(yīng)蛋白（hs-CRP）和白細(xì)胞介素-6（IL-6）水平。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為69.81%、88.68%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組心電圖改善總有效率為67.92%，顯著低于治療組的86.79%，兩組患者心電圖改善情況比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組心絞痛發(fā)作次數(shù)和持續(xù)時(shí)間均顯著下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組患者臨床癥狀改善情況優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組TG、CHO、LDL-C血脂水平、hs-CRP和IL-6水平均顯著降低（P<0.05）；且治療組這些指標(biāo)降低水平優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 阿托伐他汀聯(lián)合單硝酸異山梨酯治療冠心病心絞痛效果顯著，可有效改善臨床癥狀、血脂水平和炎性反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical efficacy of atorvastatin combined with isosorbide mononitrate in treatment of coronary heart disease with angina pectoris. Methods Patients (106 cases) with coronary heart disease with angina pectoris in Pingmei Shenma Medical Group General Hospital from July 2015 to June 2016 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were po administered with Isosorbide Mononitrate Tablets, 20 mg/time, twice daily. Patients in the treatment group were po administered with Atorvastatin Calcium Tablets on the basis of the control group, 20 mg/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy, clinical symptoms and electrocardiogram in two groups before and after treatment were compared, and the levels of TG, CHO, LDL-C, hs-CRP, and IL-6 in two groups were evaluated. Results After treatment, the clinical efficacies in the control and treatment groups were 69.81% and 88.68%, respectively, and there was difference between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the clinical symptoms in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the improvement rate of electrocardiogram in the control was 67.92%, which was significantly lower than 86.79% in the treatment group, and there was difference between two groups (P<0.05). After treatment, TG, CHO, LDL-C, hs-CRP, and IL-6 levels in two groups were significantly decreased (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Atorvastatin combined with isosorbide mononitrate has significant clinical effect in treatment of coronary heart disease with angina pectoris, can effectively improve the clinical symptoms, inflammatory response, and blood lipid levels, which has a certain clinical application value.